Completed PHASE2 INTERVENTIONAL 1-arm NCT00238394

Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer

A Phase II Study of AZD2171 in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma

Sponsor: National Cancer Institute (NCI)

Conditions Adult Primary Hepatocellular Carcinoma Advanced Adult Primary Liver Cancer Localized Unresectable Adult Primary Liver Cancer

Interventions cediranib maleate laboratory biomarker analysis

Updated 6 times since 2017 Last updated: Jun 4, 2013 Started: Dec 31, 2005 Primary completion: Mar 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00238394, this PHASE2 trial focuses on Adult Primary Hepatocellular Carcinoma and Advanced Adult Primary Liver Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States